49 related articles for article (PubMed ID: 38730680)
1. FDG-PET in Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy Toxicity: A Systematic Review.
Al-Ibraheem A; Abdlkadir AS; Lopci E; Allouzi S; Paez D; Alkuwari M; Makoseh M; Novruzov F; Usmani S; Al-Rabi K; Mansour A
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730680
[TBL] [Abstract][Full Text] [Related]
2. [
Gui J; Li M; Xu J; Zhang X; Mei H; Lan X
Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2308-2319. PubMed ID: 38467921
[TBL] [Abstract][Full Text] [Related]
3. Role of FDG PET/CT in Patients With Lymphoma Treated With Chimeric Antigen Receptor T-Cell Therapy: Current Concepts.
Murad V; Kohan A; Ortega C; Prica A; Veit-Haibach P; Metser U
AJR Am J Roentgenol; 2024 Mar; 222(3):e2330301. PubMed ID: 38054958
[TBL] [Abstract][Full Text] [Related]
4. PET-based radiomics signature can predict durable responses to CAR T-cell therapy in patients with large B-cell lymphoma.
Ligero M; Simó M; Carpio C; Iacoboni G; Balaguer-Montero M; Navarro V; Sánchez-Salinas MA; Bobillo S; Marín-Niebla A; Iraola-Truchuelo J; Abrisqueta P; Sala-Llonch R; Bosch F; Perez-Lopez R; Barba P
EJHaem; 2023 Nov; 4(4):1081-1088. PubMed ID: 38024636
[TBL] [Abstract][Full Text] [Related]
5. Metabolic parameters predict survival and toxicity in chimeric antigen receptor T-cell therapy-treated relapsed/refractory large B-cell lymphoma.
Ababneh HS; Ng AK; Abramson JS; Soumerai JD; Takvorian RW; Frigault MJ; Patel CG
Hematol Oncol; 2024 Jan; 42(1):e3231. PubMed ID: 37795759
[TBL] [Abstract][Full Text] [Related]
6. Baseline [
Marchal E; Palard-Novello X; Lhomme F; Meyer ME; Manson G; Devillers A; Marolleau JP; Houot R; Girard A
Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):481-489. PubMed ID: 37721580
[TBL] [Abstract][Full Text] [Related]
7. Imaging the Side Effects of CAR T Cell Therapy: A Primer for the Practicing Radiologist.
Huang S; de Jong D; Das JP; Widemon RS; Braumuller B; Paily J; Deng A; Liou C; Roa T; Huang A; Ma H; D'Souza B; Leb J; L'Hereaux J; Nguyen P; Luk L; Francescone M; Yeh R; Maccarrone V; Dercle L; Salvatore MM; Capaccione KM
Acad Radiol; 2023 Nov; 30(11):2712-2727. PubMed ID: 37394411
[TBL] [Abstract][Full Text] [Related]
8. Brain FDG-PET findings in chimeric antigen receptor T-cell therapy neurotoxicity for diffuse large B-cell lymphoma.
Morbelli S; Gambella M; Raiola AM; Ghiggi C; Bauckneht M; Raimondo TD; Lapucci C; Sambuceti G; Inglese M; Angelucci E
J Neuroimaging; 2023; 33(5):825-836. PubMed ID: 37291470
[TBL] [Abstract][Full Text] [Related]
9. Characterization of chimeric antigen receptor modified T cells expressing scFv-IL-13Rα2 after radiolabeling with
Leland P; Kumar D; Nimmagadda S; Bauer SR; Puri RK; Joshi BH
J Transl Med; 2023 Jun; 21(1):367. PubMed ID: 37286997
[TBL] [Abstract][Full Text] [Related]
10. CAR t-cell therapy in BOlogNa-NEUrotoxicity TReatment and Assessment in Lymphoma (CARBON-NEUTRAL): proposed protocol and results from an Italian study.
Pensato U; Amore G; Muccioli L; Sammali S; Rondelli F; Rinaldi R; D'Angelo R; Nicodemo M; Mondini S; Sambati L; Asioli GM; Rossi S; Santoro R; Cretella L; Ferrari S; Spinardi L; Faccioli L; Fanti S; Paccagnella A; Pierucci E; Casadei B; Pellegrini C; Zinzani PL; Bonafè M; Cortelli P; Bonifazi F; Guarino M
J Neurol; 2023 May; 270(5):2659-2673. PubMed ID: 36869888
[TBL] [Abstract][Full Text] [Related]
11. FDG-PET/CT in the Monitoring of Lymphoma Immunotherapy Response: Current Status and Future Prospects.
Al-Ibraheem A; Abdlkadir AS; Juweid ME; Al-Rabi K; Ma'koseh M; Abdel-Razeq H; Mansour A
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831405
[TBL] [Abstract][Full Text] [Related]
12. Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy.
Voltin CA; Gödel P; Beckmann L; Heger JM; Kobe C; Kutsch N; Borchmann P; Dietlein M; Herrmann K; Stelljes M; Rahbar K; Lenz G; Reinhardt HC; Teichert M; Noppeney R; Albring JC; Seifert R; von Tresckow B; Flossdorf S; Hanoun C
Hemasphere; 2023 Jan; 7(1):e817. PubMed ID: 36698613
[TBL] [Abstract][Full Text] [Related]
13. Advancements in Cancer Immunotherapies.
Roy R; Singh SK; Misra S
Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679904
[TBL] [Abstract][Full Text] [Related]
14. PET/CT in Non-Hodgkin Lymphoma: An Update.
Zanoni L; Bezzi D; Nanni C; Paccagnella A; Farina A; Broccoli A; Casadei B; Zinzani PL; Fanti S
Semin Nucl Med; 2023 May; 53(3):320-351. PubMed ID: 36522191
[TBL] [Abstract][Full Text] [Related]
15. PET/CT in Hodgkin Lymphoma: An Update.
Al-Ibraheem A; Mottaghy FM; Juweid ME
Semin Nucl Med; 2023 May; 53(3):303-319. PubMed ID: 36369090
[No Abstract] [Full Text] [Related]
16. Metabolic Imaging in B-Cell Lymphomas during CAR-T Cell Therapy.
Linguanti F; Abenavoli EM; Berti V; Lopci E
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230629
[TBL] [Abstract][Full Text] [Related]
17. Overview of approved CAR-T therapies, ongoing clinical trials, and its impact on clinical practice.
Sengsayadeth S; Savani BN; Oluwole O; Dholaria B
EJHaem; 2022 Jan; 3(Suppl 1):6-10. PubMed ID: 35844299
[TBL] [Abstract][Full Text] [Related]
18. Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography.
Sakemura R; Cox MJ; Bansal A; Roman CM; Hefazi M; Vernon CJ; Glynn DL; Pandey MK; DeGrado TR; Siegler EL; Kenderian SS
J Vis Exp; 2022 Feb; (180):. PubMed ID: 35253798
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
